The prostate cancer prevention trial: Current status

Journal of Urology

Volumn 171, Issue 2 SUPPL., 2004, Pages

  Higgins, Betsy ^a   Thompson, Ian M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Clinical trials; Prevention; Prostatic neoplasms

Indexed keywords

EID: 0347759930     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000107440.15626.11     Document Type: Article

References (16)

1. T.E. Thigpen, D.L. Davis, T. Gautier, J. Imperato-McGinley, D.W. Russell Brief report: the molecular basis of steroid five alpha-reductase deficiency in a large Dominican kindred N Engl J Med 327 1992 1216
2. J. Imperato-McGinley, T. Gautier, K. Zirinsky, T. Hom, O. Palomo, E. Stein Prostate visualization studies in males homozygous and heterozygous for five alpha-reductase deficiency J Clin Endocrinol Metab 75 1992 1022
3. I. Balic, S.T. Graham, D.A. Troyer, B. Higgins, B.H. Pollock, T. Johnson-Pais Androgen receptor length polymorphism associated with prostate cancer risk in Hispanics J Urol 168 2002 2245
4. E. Barrett-Connor, C. Garland, J.B. McPhillips, K.T. Khaw, D.L. Wingard A prospective, population-based study of androstenedione, estrogens, and prostatic cancer Cancer Res 50 1990 169
5. A.W. Meikle, W.M. Stanish Familial prostatic cancer risk and low testosterone J Clin Endocrinol Metab 54 1982 1104
6. R.K. Ross, L. Bernstein, R.A. Lobo, H. Shimizu, F.Z. Stanczyk, M.C. Pike 5-Alpha reductase activity and risk of prostate cancer among Japanese and US White and black males Lancet 339 1992 887
7. S. Tsukamoto, H. Akaza, M. Onozawa, T. Shirai, Y. Ideyama A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats Cancer 82 1998 531
8. W.J. Catalona, D.S. Smith, T.L. Ratliff, J.W. Basler Detection of organ-confined prostate cancer is increased through prostate-specific antigen based testing JAMA 270 1993 948
9. M.K. Brawer, M.P. Chetner, J. Beatie, D.M. Buchner, R.L. Vessella, P.H. Lange Screening for prostate cancer with prostate specific antigen J Urol 147 1992 841
10. C.G. Roehrborn Meta-analysis of randomized clinical trials of finasteride Urology 51 1998 46
11. M.J. Marberger Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study Urology 51 1998 677
12. B.B. Cantrell, D.P. DeKlerk, J.C. Eggleston, J.K. Boinott, P.C. Walsh Pathologic factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade J Urol 125 1981 516
13. G. Andriole, H. Guess, J.I. Epstein, F. Wise, D. Kadmon, E.D. Crawford Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial Urology 52 1998 195
14. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, L.G. Ford The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 211
15. F. Civantos, M.S. Soloway, J.E. Pinto Histopathological effects of androgen deprivation in prostatic cancer Semin Urol Oncol 14 1996 22
16. D.G. Bostwick Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation Anat Pathol 3 1998 1